WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards
WuXi Biologics (2269.HK) has secured five prestigious awards at the 2025 Asia-Pacific Biopharma Excellence Awards, marking their seventh recognition by the organizer. The awards include Best CDMO, Best Aseptic Fill-Finish & Packaging CMO, Best Drug Delivery Systems Supplier, Best New Modalities Manufacturing Company, and Best Bioprocessing Supplier for Cell Line Development.
The company showcases impressive capabilities with 151 bispecifics & multispecifics, 194 ADCs, 80 fusion proteins and 24 vaccines in their portfolio. They've achieved notable efficiency by reducing monoclonal antibody development time to 9 months from DNA to IND, with one autoimmune project completed in just 6 months. Their manufacturing success rate stands at 99% (2022-2024), with facilities scaling from 4,000 to 16,000 liters using single-use technology.
WuXi Biologics maintains exceptional quality standards, having passed 42 global regulatory inspections, including 22 by FDA and EMA, with a 100% success rate in Pre-License Inspections. Their WuXia™ platform yields up to 11 g/L and has generated over 900 cell lines for clinical and commercial manufacturing.
WuXi Biologics (2269.HK) ha ricevuto cinque prestigiosi premi agli Asia-Pacific Biopharma Excellence Awards 2025, segnando il loro settimo riconoscimento da parte dell'organizzatore. I premi includono il Miglior CDMO, il Miglior CMO per Riempimento e Confezionamento Aseptico, il Miglior Fornitore di Sistemi di Somministrazione di Farmaci, la Miglior Azienda di Produzione di Nuove Modalità e il Miglior Fornitore di Bioprocessing per lo Sviluppo di Linee Cellulari.
L'azienda dimostra capacità impressionanti con 151 bispecifici e multispecifici, 194 ADC, 80 proteine fusione e 24 vaccini nel loro portafoglio. Hanno raggiunto un'efficienza notevole riducendo il tempo di sviluppo degli anticorpi monoclonali a 9 mesi dal DNA all'IND, con un progetto autoimmune completato in soli 6 mesi. Il loro tasso di successo nella produzione si attesta al 99% (2022-2024), con strutture che scalano da 4.000 a 16.000 litri utilizzando tecnologia monouso.
WuXi Biologics mantiene standard di qualità eccezionali, avendo superato 42 ispezioni normative globali, incluse 22 da parte della FDA e dell'EMA, con un tasso di successo del 100% nelle Ispezioni Pre-Licenza. La loro piattaforma WuXia™ produce fino a 11 g/L e ha generato oltre 900 linee cellulari per la produzione clinica e commerciale.
WuXi Biologics (2269.HK) ha conseguido cinco prestigiosos premios en los Asia-Pacific Biopharma Excellence Awards 2025, marcando su séptimo reconocimiento por parte del organizador. Los premios incluyen Mejor CDMO, Mejor CMO de Llenado y Acabado Aseptico, Mejor Proveedor de Sistemas de Entrega de Medicamentos, Mejor Empresa de Fabricación de Nuevas Modalidades y Mejor Proveedor de Bioprocesamiento para el Desarrollo de Líneas Celulares.
La empresa muestra capacidades impresionantes con 151 bispecíficos y multispecíficos, 194 ADC, 80 proteínas de fusión y 24 vacunas en su cartera. Han logrado una notable eficiencia al reducir el tiempo de desarrollo de anticuerpos monoclonales a 9 meses desde el ADN hasta el IND, con un proyecto autoinmune completado en solo 6 meses. Su tasa de éxito en la fabricación se sitúa en 99% (2022-2024), con instalaciones que escalan de 4,000 a 16,000 litros utilizando tecnología de un solo uso.
WuXi Biologics mantiene estándares de calidad excepcionales, habiendo pasado 42 inspecciones regulatorias globales, incluidas 22 por la FDA y la EMA, con una tasa de éxito del 100% en Inspecciones Pre-Licencia. Su plataforma WuXia™ produce hasta 11 g/L y ha generado más de 900 líneas celulares para fabricación clínica y comercial.
우시 바이오로직스 (2269.HK)는 2025 아시아-태평양 바이오제약 우수상에서 다섯 개의 권위 있는 상을 수상하며, 주최자로부터 일곱 번째 인정을 받았습니다. 수상 항목에는 최우수 CDMO, 최우수 무균 충전 및 포장 CMO, 최우수 약물 전달 시스템 공급업체, 최우수 신규 방식 제조 회사, 그리고 세포주 개발을 위한 최우수 생물 처리 공급업체가 포함됩니다.
회사는 151개의 이중 특이성 및 다중 특이성 항체, 194개의 ADC, 80개의 융합 단백질 및 24개의 백신을 보유한 인상적인 능력을 보여줍니다. 그들은 DNA에서 IND까지의 단클론 항체 개발 시간을 9개월로 단축하여 눈에 띄는 효율성을 달성했으며, 자가면역 프로젝트는 단 6개월 만에 완료되었습니다. 그들의 제조 성공률은 99% (2022-2024)이며, 시설은 4,000리터에서 16,000리터로 단일 사용 기술을 사용하여 확장하고 있습니다.
우시 바이오로직스는 42개의 글로벌 규제 검사에서 100% 성공률을 기록하며, FDA와 EMA의 22개 검사를 포함하여 뛰어난 품질 기준을 유지하고 있습니다. 그들의 WuXia™ 플랫폼은 최대 11 g/L를 생산하며, 임상 및 상업적 제조를 위한 900개 이상의 세포주를 생성했습니다.
WuXi Biologics (2269.HK) a obtenu cinq prix prestigieux lors des Asia-Pacific Biopharma Excellence Awards 2025, marquant leur septième reconnaissance par l'organisateur. Les prix comprennent Meilleur CDMO, Meilleur CMO de Remplissage et d'Emballage Aseptique, Meilleur Fournisseur de Systèmes de Distribution de Médicaments, Meilleure Entreprise de Fabrication de Nouvelles Modalités et Meilleur Fournisseur de Bioprocédés pour le Développement de Lignes Cellulaires.
L'entreprise démontre des capacités impressionnantes avec 151 bispécifiques et multispecifiques, 194 ADC, 80 protéines de fusion et 24 vaccins dans son portefeuille. Ils ont atteint une efficacité notable en réduisant le temps de développement des anticorps monoclonaux à 9 mois depuis l'ADN jusqu'à l'IND, avec un projet auto-immun terminé en seulement 6 mois. Leur taux de réussite en fabrication est de 99% (2022-2024), avec des installations passant de 4 000 à 16 000 litres en utilisant une technologie à usage unique.
WuXi Biologics maintient des normes de qualité exceptionnelles, ayant réussi 42 inspections réglementaires mondiales, dont 22 par la FDA et l'EMA, avec un taux de réussite de 100 % lors des inspections préalables à la licence. Leur plateforme WuXia™ produit jusqu'à 11 g/L et a généré plus de 900 lignées cellulaires pour la fabrication clinique et commerciale.
WuXi Biologics (2269.HK) hat bei den Asia-Pacific Biopharma Excellence Awards 2025 fünf prestigeträchtige Auszeichnungen gewonnen und damit ihre siebte Anerkennung durch den Veranstalter erhalten. Die Auszeichnungen umfassen Besten CDMO, Besten aseptischen Füll- und Verpackungs-CMO, Besten Lieferanten von Arzneimittelabgabesystemen, Beste Produktionsfirma für neue Modalitäten und Besten Bioprozesslieferanten für die Zelllinienentwicklung.
Das Unternehmen zeigt beeindruckende Fähigkeiten mit 151 bispezifischen und multispezifischen Antikörpern, 194 ADCs, 80 Fusionsproteinen und 24 Impfstoffen in seinem Portfolio. Sie haben bemerkenswerte Effizienz erreicht, indem sie die Entwicklungszeit für monoklonale Antikörper von DNA bis IND auf 9 Monate verkürzt haben, wobei ein Autoimmunprojekt in nur 6 Monaten abgeschlossen wurde. Ihre Erfolgsquote in der Herstellung liegt bei 99% (2022-2024), mit Anlagen, die von 4.000 auf 16.000 Liter mit Einwegtechnologie skaliert werden.
WuXi Biologics hält außergewöhnliche Qualitätsstandards ein und hat 42 globale regulatorische Inspektionen bestanden, darunter 22 von der FDA und der EMA, mit einer Erfolgsquote von 100% bei Vorlizenzinspektionen. Ihre WuXia™-Plattform erzielt bis zu 11 g/L und hat über 900 Zelllinien für die klinische und kommerzielle Herstellung generiert.
- None.
- None.
- Best Contract Development and Manufacturing Organization Award
- Best Aseptic Fill-Finish & Packaging CMO of the Year
- Best Aseptic Fill-Finish & Packaging Supplier Award: Drug Delivery Systems
- Best New Modalities Manufacturing Company
- Best Bioprocessing Supplier Award: Cell Line Development & Characterization
WuXi Biologics is committed to advancing integrated technology platforms that accelerate biologics discovery, development, and manufacturing. It has one of the largest portfolios of complex biologics in the industry, including 151 bispecifics & multispecifics, 194 ADCs, 80 fusion proteins and 24 vaccines.The development time for monoclonal antibody projects from DNA to Investigational New Drug (IND) application has been shortened to 9 months, with a recent autoimmune disease project completed in just 6 months. By leveraging single-use technology (SUT), the company scaled manufacturing from 4,000 to 16,000 liters across its global facilities, achieving a
WuXi Biologics' high-yielding mammalian cell line platform WuXia™ (up to about 11 g/L) has been widely accepted in the industry and regulatory agencies worldwide. It has generated over 900 cell lines expressing monoclonal and bispecific antibodies, fusion proteins, enzymes and other recombinant proteins for clinical and commercial manufacturing. It has also launched WuXiaADCC Plus™, a superior-performing and high-yielding mammalian cell line platform for the development and manufacturing of afucosylated antibodies to elicit an enhanced ADCC response, and WuXia RidGS™, a high-yield glutamine synthetase (GS)-knockout CHO expression system, catering to the diverse needs of global clients.
WuXi Biologics delivers advanced drug product (DP) development services for biologics, vaccines and small molecule parenterals. Its capabilities include the development of liquid, frozen, and lyophlized dosage forms, complemented by proficiency in diverse container closure systems (CCS) that include vials and combination products such as pre-filled syringes (PFS), PFS with needle safety devices (NSD) and autoinjectors. Furthermore, the company operates multiple state-of-the-art DP manufacturing facilities for the formulation, filling, labelling, and packaging of biotherapeutics, vaccines, placebo and parenterals filled into either liquid or lyophilized dosage forms.
Dr. Chris Chen, CEO of WuXi Biologics, commented, "The numerous accolades earned by WuXi Biologics stand as a powerful testament to the value we deliver to global clients and the broader industry. Through our relentless pursuit of excellence, uncompromising quality standards, visionary leadership, and the dedication of our talented global team, we remain steadfast in enabling partners to accelerate groundbreaking therapies—bringing life-changing treatments to patients around the world."
Sponsored by IMAPAC, a leading consulting firm in the biopharmaceutical industry, the ABEA seeks to recognize the outstanding achievements of top leaders in biomanufacturing, biologistics and clinical trials, applauding extraordinary leaders and trendsetters of today, and inspiring innovators of tomorrow. Finalists for each award category are shortlisted based on the volume of nominations received and a rigorous internal evaluation of merit. The ultimate winners are determined by votes from the global biopharma community, ensuring an unbiased and industry-driven outcome.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
Media
PR@wuxibiologics.com
Business
info@wuxibiologics.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-wins-five-asia-pacific-biopharma-excellence-awards-302427623.html
SOURCE WuXi Biologics
FAQ
What awards did WuXi Biologics (WXXWY) win at the 2025 Asia-Pacific Biopharma Excellence Awards?
What is the current manufacturing success rate of WuXi Biologics (WXXWY) between 2022-2024?
How many regulatory inspections has WuXi Biologics (WXXWY) passed and from which agencies?
What is the development timeline for monoclonal antibody projects at WuXi Biologics (WXXWY)?
How many cell lines has WuXi Biologics' (WXXWY) WuXia platform generated and what is its yield capacity?
